000			01954 a2200517 4500
005			20250516063030.0
264		0	_c20120411
008			201204s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mdr515 _2doi
040			_aNLM _beng _cNLM
100	1		_aHartl, D M
245	0	0	_aBevacizumab-induced laryngeal necrosis. _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _cJan 2012
300			_a276-278 p. _bdigital
500			_aPublication Type: Case Reports; Letter
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aBevacizumab
650	0	4	_aCarboplatin _xadministration & dosage
650	0	4	_aCisplatin _xadministration & dosage
650	0	4	_aClinical Trials, Phase I as Topic
650	0	4	_aDeoxycytidine _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aGlutamates _xadministration & dosage
650	0	4	_aGuanine _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aLaryngeal Diseases _xchemically induced
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMiddle Aged
650	0	4	_aNecrosis _xchemically induced
650	0	4	_aNeoplasm Recurrence, Local _xdrug therapy
650	0	4	_aPaclitaxel _xadministration & dosage
650	0	4	_aPemetrexed
650	0	4	_aTubulin Modulators _xadministration & dosage
650	0	4	_aGemcitabine
700	1		_aBahleda, R
700	1		_aHollebecque, A
700	1		_aBosq, J
700	1		_aMassard, C
700	1		_aSoria, J C
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 23 _gno. 1 _gp. 276-278
856	4	0	_uhttps://doi.org/10.1093/annonc/mdr515 _zAvailable from publisher's website
999			_c21286581 _d21286581